Cargando…

Evaluation of hepatic integrin αvβ3 expression in non-alcoholic steatohepatitis (NASH) model mouse by (18)F-FPP-RGD(2) PET

BACKGROUND: Activated hepatic stellate cells (HSCs), which express integrin αvβ3, are a major fibrogenic factor in NASH pathophysiology. (18)F-labeled cyclic arginine-glycine-aspartic acid penta-peptide ((18)F-FPP-RGD(2)) has been used as a PET probe for tumors expressing integrin αvβ3. The aim of t...

Descripción completa

Detalles Bibliográficos
Autores principales: Rokugawa, Takemi, Konishi, Haruyo, Ito, Miwa, Iimori, Hitoshi, Nagai, Ryohei, Shimosegawa, Eku, Hatazawa, Jun, Abe, Kohji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5981157/
https://www.ncbi.nlm.nih.gov/pubmed/29855729
http://dx.doi.org/10.1186/s13550-018-0394-4
Descripción
Sumario:BACKGROUND: Activated hepatic stellate cells (HSCs), which express integrin αvβ3, are a major fibrogenic factor in NASH pathophysiology. (18)F-labeled cyclic arginine-glycine-aspartic acid penta-peptide ((18)F-FPP-RGD(2)) has been used as a PET probe for tumors expressing integrin αvβ3. The aim of this study was to assess the potential of PET with (18)F-FPP-RGD(2) to detect hepatic integrin αvβ3 expression in non-alcoholic steatohepatitis (NASH) model mice. RESULTS: Thirty-two male C57BL/6 mice aged 6 weeks were fed a choline-deficient, l-amino acid-defined, high-fat diet (CDAHFD) for 3 and 8 weeks. (18)F-FPP-RGD(2) PET imaging of the liver was performed at 3 and 8 weeks after CDAHFD feeding. After PET scanning, levels of hepatic integrin αvβ, 3α-smooth muscle actin (α-SMA), and collagen type 1 alpha 1(col1a1) were measured. Histopathological analysis of hepatic steatosis, inflammation, and fibrosis, as well as blood biochemistry analysis, was also performed. CDAHFD for 3 and 8 weeks produced a moderate-to-severe steatosis and inflammation of the liver in mice. NAFLD activity score (NAS) in mice fed the CDAHFD for 3 and 8 weeks were more than 4 indicating NASH or borderline NASH pathology. Fibrosis was observed only in mice fed the CDAHFD for 8 weeks. PET imaging showed that the hepatic standardized uptake value, SUV(80–90 min), was increased with prolonged CDAHFD feeding compared with the respective controls (CDAHFD 3 weeks 0.32 ± 0.06 vs 0.48 ± 0.05, p < 0.01; CDAHFD 8 weeks 0.35 ± 0.04 vs 0.75 ± 0.07, p < 0.01, respectively). Prolonged CDAHFD feeding increased hepatic mRNA and protein levels of integrin αv and β3 at 3 and 8 weeks. Hepatic (18)F-FPP-RGD(2) uptake and amount of integrin αv and β3 protein were well correlated (r = 0.593, p < 0.05 and r = 0.835, p < 0.001, respectively). Hepatic (18)F-FPP-RGD(2) uptake also showed a positive correlation with Sirius red-positive area. CONCLUSIONS: The hepatic uptake of (18)F-FPP-RGD(2) correlated well with integrin αv and β3 expression and histological fibrosis in a mouse model of NASH, suggesting the predictability of fibrosis in NASH pathology.